These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 19223501)

  • 21. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance.
    van Gils MP; Hessels D; van Hooij O; Jannink SA; Peelen WP; Hanssen SL; Witjes JA; Cornel EB; Karthaus HF; Smits GA; Dijkman GA; Mulders PF; Schalken JA
    Clin Cancer Res; 2007 Feb; 13(3):939-43. PubMed ID: 17289888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells.
    Medeiros R; Morais A; Vasconcelos A; Costa S; Pinto D; Oliveira J; Carvalho R; Lopes C
    Prostate; 2002 Sep; 53(1):88-94. PubMed ID: 12210484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population.
    Parekh DJ; Ankerst DP; Higgins BA; Hernandez J; Canby-Hagino E; Brand T; Troyer DA; Leach RJ; Thompson IM
    Urology; 2006 Dec; 68(6):1152-5. PubMed ID: 17169636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.
    Welch HG; Fisher ES; Gottlieb DJ; Barry MJ
    J Natl Cancer Inst; 2007 Sep; 99(18):1395-400. PubMed ID: 17848671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer.
    Tanaka N; Fujimoto K; Yoshikawa M; Tanaka M; Hirao Y; Kondo H; Saito I
    Hinyokika Kiyo; 2007 Jul; 53(7):459-65. PubMed ID: 17702178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PCA3: a molecular urine assay for predicting prostate biopsy outcome.
    Deras IL; Aubin SM; Blase A; Day JR; Koo S; Partin AW; Ellis WJ; Marks LS; Fradet Y; Rittenhouse H; Groskopf J
    J Urol; 2008 Apr; 179(4):1587-92. PubMed ID: 18295257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men.
    Ghafoori M; Varedi P; Hosseini SJ; Asgari M; Shakiba M
    Urol J; 2009; 6(3):182-8. PubMed ID: 19711272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between Toll-like receptor gene cluster (TLR6, TLR1, and TLR10) and prostate cancer.
    Chen YC; Giovannucci E; Kraft P; Lazarus R; Hunter DJ
    Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):1982-9. PubMed ID: 17932345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effectiveness of screening for prostate cancer: a nested case-control study.
    Concato J; Wells CK; Horwitz RI; Penson D; Fincke G; Berlowitz DR; Froehlich G; Blake D; Vickers MA; Gehr GA; Raheb NH; Sullivan G; Peduzzi P
    Arch Intern Med; 2006 Jan; 166(1):38-43. PubMed ID: 16401808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients.
    Suzuki H; Komiya A; Kamiya N; Imamoto T; Kawamura K; Miura J; Suzuki N; Nakatsu H; Hata A; Ichikawa T
    Urology; 2006 Jan; 67(1):131-6. PubMed ID: 16413348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alpha 1 antichymotrypsin genotype is associated with increased risk of prostate carcinoma and PSA levels.
    Licastro F; Bertaccini A; Porcellini E; Chiappelli M; Pernetti R; Sanguedolce F; Marchiori D; Martorana G
    Anticancer Res; 2008; 28(1B):395-9. PubMed ID: 18383875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for prostate cancer patients with intermediate PSA levels.
    Tanaka N; Fujimoto K; Chihara Y; Torimoto M; Hirao Y; Konishi N; Saito I
    Prostate Cancer Prostatic Dis; 2007; 10(3):274-8. PubMed ID: 17339878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection.
    Chiang IN; Chang SJ; Pu YS; Huang KH; Yu HJ; Huang CY
    Urol Int; 2009; 82(3):270-5. PubMed ID: 19440012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility.
    Lai J; Kedda MA; Hinze K; Smith RL; Yaxley J; Spurdle AB; Morris CP; Harris J; Clements JA
    Carcinogenesis; 2007 May; 28(5):1032-9. PubMed ID: 17151093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Free PSA/total PSA ratio increases the detection rate of prostate cancer in twelve-core biopsy.
    Yokomizo Y; Miyoshi Y; Nakaigawa N; Makiyama K; Ogawa T; Yao M; Kubota Y; Uemura H
    Urol Int; 2009; 82(3):280-5. PubMed ID: 19440014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of multiple genetic polymorphisms on genitourinary morbidity after carbon ion radiotherapy for prostate cancer.
    Suga T; Iwakawa M; Tsuji H; Ishikawa H; Oda E; Noda S; Otsuka Y; Ishikawa A; Ishikawa K; Shimazaki J; Mizoe JE; Tsujii H; Imai T
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):808-13. PubMed ID: 18374504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The presence of prostate cancer at biopsy is predicted by a number of genetic variants.
    Kashyap A; Kluźniak W; Wokołorczyk D; Gołąb A; Sikorski A; Słojewski M; Gliniewicz B; Świtała J; Borkowski T; Borkowski A; Antczak A; Wojnar Ł; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Sikorska-Radek P; Matych J; Wilkosz J; Różański W; Kiś J; Bar K; Bryniarski P; Paradysz A; Jersak K; Niemirowicz J; Słupski P; Jarzemski P; Skrzypczyk M; Dobruch J; Domagała P; Piotrowski K; Jakubowska A; Gronwald J; Huzarski T; Byrski T; Dębniak T; Górski B; Masojć B; van de Wetering T; Menkiszak J; Akbari MR; Lubiński J; Narod SA; Cybulski C;
    Int J Cancer; 2014 Mar; 134(5):1139-46. PubMed ID: 24037955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of a nomogram for predicting positive repeat biopsy for prostate cancer.
    Yanke BV; Gonen M; Scardino PT; Kattan MW
    J Urol; 2005 Feb; 173(2):421-4. PubMed ID: 15643192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate cancer screening in men with a family history of prostate cancer: the role of partners in influencing men's screening uptake.
    Meiser B; Cowan R; Costello A; Giles GG; Lindeman GJ; Gaff CL
    Urology; 2007 Oct; 70(4):738-42. PubMed ID: 17991547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3.
    Perdonà S; Cavadas V; Di Lorenzo G; Damiano R; Chiappetta G; Del Prete P; Franco R; Azzarito G; Scala S; Arra C; De Sio M; Autorino R
    Eur Urol; 2011 Jan; 59(1):81-7. PubMed ID: 20947244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.